Frontline Plc Ordinary Shares vs 22nd Century Group Inc — how do they compare? Frontline Plc Ordinary Shares trades at $55.86 (market cap $11.81B), while 22nd Century Group Inc trades at $0.89 (market cap $627.17K). The key difference: Frontline Plc Ordinary Shares is far larger — about 18830.6× 22nd Century Group Inc's market cap, and Frontline Plc Ordinary Shares pays a 10.14% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Frontline Plc Ordinary Shares for 0 Days and 22nd Century Group Inc for 32 Days on average.
| FRO | XXII | |
|---|---|---|
Market Cap | $11.81B | $627.17K |
Volume | 3,013,086 | 42,481 |
Sector | Industrials | Consumer Staples |
52-Week High | $56.26 | $483.00 |
52-Week Low | $20.58 | $0.80 |
Typical Hold Time | 0 Days | 32 Days |
Enterprise Value | $13.92B | -$3.68M |
Dividend Yield | 10.14% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Frontline operates a fleet of oil tankers that transport crude oil by sea. Its vessels serve global energy trading routes.
Read more on FRO →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →